December 20, 2021 -- Sartorius is acquiring a majority stake in ALS Automated Lab Solutions. Sartorius is initially purchasing 62.5% of the shares in ALS as of January 3, 2022. The remaining 37.5% will be acquired in 2026.
ALS Automated Lab Solutions develops, manufactures, and sells automated solutions for life sciences companies in a range of areas, including molecular diagnostics, cancer and stem cell research, cell line development, and bioprocessing.
ALS currently employs approximately 30 people in Jena, Germany, and is expected to generate sales in the high single-digit million-euro range in 2021. The Sartorius Group is an international partner of life science research and the biopharmaceutical industry. At the end of 2020, nearly 11,000 people were employed at the group's approximately 60 manufacturing and sales sites.
The companies did not disclose the terms of the financial agreements.
Copyright © 2021 scienceboard.net